New prostate drug delivered directly to target

NCT ID NCT07264205

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tests a new treatment called RT-310 for men with enlarged prostate (BPH) who have bothersome urinary symptoms. RT-310 is a drug delivered directly into the prostate to reduce side effects. The study will check if it is safe and feasible in 20 men aged 50 to 80.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

RT-310 (a drug delivered directly to the prostate)

What this could lead to

If it works, this could lead to a new treatment for BPH that reduces side effects by targeting the prostate directly.

What could go wrong

This is a very early, small study (20 men) focused only on safety and feasibility. It may not show clear benefit, and the approach might not work in larger trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BPH (BENIGN PROSTATIC HYPERPLASIA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

benign prostatic hyperplasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Research Site

    Santo Domingo, Dominican Republic